Skip to main content
editorial
. 2020 Jul 15;72(10):1823–1825. doi: 10.1093/cid/ciaa982

Table 1.

Representative Implementation Research Approach in Africa to Investigate the Efavirenz-Dolutegravir Pharmacokinetic Interaction in Second-line Treatment Regimens

Gap for Second-line Dolutegravir Implementation Research Organization Contribution
Dolutegravir rollout sponsor PEPFAR Multiple country organization for implementing dolutegravir access
Clinical care site Hospital-based clinic, Ministry of Health Clinic Recruitment of participants into protocol
Clinical research unit NIAID/DAIDS Clinical Trials Units Study design, regulatory compliance, staff mentoring
Research and training Fogarty International Center Funding for HIV research and training programs, support for pilot research projects for scholars
Pharmacogenomics H3Africa Laboratory technology for genotyping, sample collection, and transport guidelines
Pharmacovigilance Pharmacovigilance System in Sub-Saharan Africa Umbrella organization for organizing the implementation research project
Pharmacokinetics Clinical Pharmacology Laboratories (eg, South Africa, Zimbabwe, Uganda) Bioanalysis research with required mass spectrometry instrumentation, validated drug assays
Data collection and harmonization IeDEA Cohort Consortium Data collection to facilitate multiple clinical research sites, data analysis

Abbreviations: HIV, human immunodeficiency virus; IeDEA, International Epidemiology Databases to Evaluate AIDS; NIAID/DAIDS, National Institute of Allergy and Infectious Diseases, Division of AIDS; PEPFAR, US President’s Emergency Plan For AIDS Relief.